Australian Operations


Media Enquiries

Melanie Kerin
Senior Manager, Communications
Mobile: +61 (0) 417436329 

Afluria Quad™ – a four strain flu vaccine manufactured in Australia is now available
A quadrivalent flu vaccine manufactured by Seqirus locally in Melbourne, Australia is available for the 2017 Australian flu season for adults aged 18 years and older. More.

Majority of Aussies Unprepared for Close Encounters with Venomous Creatures
New research finds just one in five (20%) Aussies are familiar with emergency treatment for venomous bites and stings while younger Australians, aged under 25, are at greatest risk, showing the least amount of knowledge in treating bites and stings. More.

Seqirus and Zambon in partnership for Parkinson’s Disease product in Australia and New Zealand
Zambon and Seqirus today announced that they have entered into a long term partnership covering Zambon's Parkinson's Disease product, in Australia and New Zealand. More.

Seqirus donates vaccines to Fiji to alleviate increase in influenza
Seqirus today announced the donation of 20,000 doses of seasonal influenza vaccine to the people of Fiji in order to help alleviate a spike in cases of severe influenza. More.

CSL completes Novartis influenza vaccine business acquisition
CSL Limited (ASX:CSL; USOTC: CSLLY) today announced that it has now closed its transaction to acquire Novartis global influenza vaccine business for a cash consideration of US$275 million. More.

Update on Novartis influenza vaccines acquisition
CSL Limited (ASX:CSL; USOTC: CSLLY) today announced that it has secured the necessary approvals required to proceed with the acquisition of the influenza vaccines business of Novartis and that it is working with Novartis to bring forward the close date for the transaction. The Company also said the new CSL subsidiary resulting from the acquisition will be called Seqirus. More.

CSL Acquires Exclusive Rights to Influenza Treatment
CSL Limited (ASX:CSL) today announced it has acquired exclusive rights to commercialise the influenza treatment, RAPIVAB®, from US-based company, BioCryst Pharmaceuticals Inc (NASDAQ: BCRX). More.



Media Enquiries

Melanie Kerin
Senior Manager, Communications, 
Mobile: +61 (0) 417436329 

LinkedIn Twitter Facebook Google+